ICMR invites partners to launch and sell its new malaria vaccine

Malaria is a parasitic infection sent by mosquitoes. While the current vaccine prevents the most common people that cause infection in humans called Plasmodium Phalsiparum, there are at least four other parasites from the same family that are considered the cause of infection in humans.

P. Vivax is the second one that usually causes malaria infection, especially in India. Others – P Malaria, P Owale, and P Nolsi – cause low infections. While pre-nervous studies have already shown positive signs, the company collaborating with ICMR will be responsible for further development, human clinical tests and scale-up for commercial production.

The vaccine contains the genetic material of two goals – for a major protein called CSP, which is found on the surface of the malaria parasite and another for combining parts of two proteins that affect the life cycle of the pathogen.

“The market currently has some significant differences in ICMR vaccine than the other two. One, one, this vaccine used DNA for the entire CSP protein instead of some parts, which means that it is likely to produce a strong immune response. The vaccine, but the pathological life, prevents the spread of the disease by disrupting the disease cycle, even when it lifted the spread of the disease, even when it lifted a mosquito from a mosquito before a mosquito before a mosquito. If gone, it is raised by an infected person for further transmission.

Senior scientist Dr. Sushil Singh and director Dr. Sanghamitra Pati was part of the development process. Former-nineric verification was done in collaboration with ICMR-Nanational Institute of Medical Research and National Institute of Immunology.